{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-017653","form_type":"8-K","ticker":null,"cik":"0000727207","company_name":"Accelerate Diagnostics, Inc","filed_at":"2023-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.906039+00:00","generated_at":"2026-06-19T21:08:23.312599+00:00","sec_items":["4.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Accelerate Diagnostics restates 2022 quarterly reports; notes misclassification, going concern doubt","bullets":["Restating Q1-Q3 2022 interim financials due to misclassification of $56.6M of 2.50% Senior Convertible Notes as non-current liability.","Previously issued $171.5M notes; exchanged $114.9M for stock, promissory note, and warrants between Sep 2021 and Aug 2022.","Amended 10-Qs will include disclosure expressing substantial doubt about ability to continue as a going concern.","Management expects to report material weakness in internal control over financial reporting for affected periods.","Restatement does not materially impact statements of operations, cash flows, or stockholders' deficit."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-017653","json":"https://secwatch.observer/filing/0001104659-23-017653.json","markdown":"https://secwatch.observer/filing/0001104659-23-017653.md","text":"https://secwatch.observer/filing/0001104659-23-017653.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/727207/000110465923017653/0001104659-23-017653-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/727207/000110465923017653/tm236096d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T21:08:23.312599+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3b8aa7c6801c02e7bb572cf661a5a273f7d7b0a4","claim":"Accelerate Diagnostics, Inc reported that prior financial statements should not be relied upon.","evidence_excerpt":"hould no longer be relied upon due to the error in the balance sheet classification of the Company’s 2.50% Senior Convertible Notes due 2023 (the “Notes”) described below. In March and April 2018, the Company issued $171.5 million aggregate principal amount of Notes, which have a maturity date of March 15, 2023, unless earlier converted or repurchased. Between September 2021 and August 2022, the Company entered into certain exchange transactions pursuant to which the Company exchanged $114.9 million aggregate principal amount of Notes for one or a combination of: shares of the Company’s common stock, a secured promissory note and/or warrants to purchase the Company’s common stock. As of the date of this Current Report on Form 8-K, $56.6 million aggregate principal amount of Notes remain outstanding. The balance sheets contained in each of the 2022 Interim Financial Statements classified","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/727207/000110465923017653/0001104659-23-017653-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"non reliance"},{"label":"Auditor","value":"Ernst & Young LLP"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}